TopoⅡα、GST-π、P—gp在卵巢癌化疗耐药中的作用
The Role of Topo Ⅱα,GST-π.P-gp Played in the Multidrug Resistance of the Epithelial Ovarian
查看参考文献10篇
|
文摘
|
目的 探讨TopoⅡα、GST-π、P-gp在卵巢癌化疗耐药中的作用。方法 采用免疫组化SP法、计算机图像分析技术对80例卵巢癌、20例良性上皮性卵巢肿瘤、20例正常卵巢组织中TopoⅡα、GST-π、P-gp的表达进行检测。结果 卵巢癌中TopoⅡα、GST-π、P-gp的表达显著高于正常组及良性肿瘤组，P〈0．05。TopoⅡα、GST-π的表达与肿瘤分化程度有关，分化越差表达越高，P〈0．05；P-gp的表达与多种病理因素无关，P〉0．05。术前化疗组GST-π、P-gp的阳性表达率显著高于术前未化疗组，P〈0．05。结论 TopoⅡα、GST-π、P-gp在卵巢癌耐药中发挥重要作用，这三项指标的联合检测对制定合理的化疗方案具有积极的指导意义。 |
|
其他语种文摘
|
Objective To investigate the role Topo Ⅱα. GST-π, P-gp played in multidrug resistance of the epithelial ovarian carcinoma. Methods The expression of Topo Ⅱα. GST-π. P-gp in 80 cases of ovarian carcinoma, 20 cases of benign ovarian tumor and 20 cases of normal control were determined by SP immunohistochemical technique. Results The positive expression rate of Topo Ⅱα,GST-π.P-gp in ovarian carcinoma was significantly higher than in benign tumors and normal tissues, P〈0. 05. A significant relationship was shown between Topo Ⅱα.GST-π expression and pathologic grade as well as clinical stage, respectively, P〈0. 05; No significant differences with P-gp expression were found in relation to the histopathology, pathelogic grade and clinical stage, P〈0. 05. The GST-π,P-gp positive expressions in cases received chemotherapy before surgery were significantly higher than in cases who didn＇ t, P〈0. 05. Conclusion These data suggested that Topo Ⅱα. GST-π, P-gp played an important role in the muhidrug resistance of the ovarian carcinoma. |
|
来源
|
肿瘤防治研究
,2006,33(3):197-199 【扩展库】
|
|
关键词
|
TopoⅡα
;
GST-π
;
P-gp
;
卵巢癌
;
耐药
|
|
地址
|
武汉大学中南医院妇瘤科, 430071
|
|
语种
|
中文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1000-8578 |
|
学科
|
肿瘤学 |
|
文献收藏号
|
CSCD:2351564
|
参考文献 共
10
共1页
|
|
1.
Parker SL. Cancer statistics.
CA Cancer J Clin,1997,47(1):5-7
|
CSCD被引
33
次
|
|
|
|
|
2.
Tanoguchi K. Immunohistochemical and two-parameter flow cytometric of DNA topoisomeraseⅡalpha in human epithelial ovarian carcinoma and gern cell tumor.
Mod Pathol,1998,11(2):186-193
|
CSCD被引
2
次
|
|
|
|
|
3.
Gotlieb WH. TopoisomeraseⅡimmunostaining as a prognostic marker for survival in ovarian cancer.
Gynecol Oncol,2001,82(1):99-104
|
CSCD被引
7
次
|
|
|
|
|
4.
Hamada SI. Expression of glutathione-S-transferase-πin human ovarian cancer as an indictor of resistance to chemotherapy.
Gynecol Oncol,1994,52(3):3134
|
CSCD被引
2
次
|
|
|
|
|
5.
Baekelandt MM. P-glycoprotein expression is a marker for chemotherapy resistance and pronosis in advance ovarian cancer.
Anticancer Res,2000,20:1061-1067
|
CSCD被引
6
次
|
|
|
|
|
6.
Mayr D. Immunohistochemical analysis of drug resistance-associated protein in ovarian carcinomas.
Pathol Res Prsct,2000,196(7):469-475
|
CSCD被引
3
次
|
|
|
|
|
7.
Koshiyama M. Correlation between TopoⅡalpha expression and chemosensitivity testing for TopoⅡ-targeting drugs in gynaccological carcinomas.
Anticancer Res,2001,21(2A):905-910
|
CSCD被引
10
次
|
|
|
|
|
8.
Chalia AA. Estimation of glutathione-s-transferase and its pi isoenzyme in tumor tissues and sera of patients with ovarian cancer.
Anticancer Res,2000,20:1229-1235
|
CSCD被引
1
次
|
|
|
|
|
9.
马琳. 卵巢癌GST-π基因的表达及其临床意义.
实用肿瘤学杂志,2000,14(4):258-259
|
CSCD被引
1
次
|
|
|
|
|
10.
Ozalp SS. Multidrug resistancer gene-1(P-gp)expression in epithelial ovarian malignances.
Eur J Gynecol Oncol,2002,23(4):337-340
|
CSCD被引
5
次
|
|
|
|
|
了解气象卫星更多信息，请访问